{
    "xml": "<topic id=\"PHP93589\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/vedolizumab\" basename=\"vedolizumab\" title=\"VEDOLIZUMAB\">\n<title>VEDOLIZUMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1344\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/vedolizumab\">Vedolizumab</xref>\n</p>\n<data name=\"vtmid\">704257002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_402717286\" title=\"Monoclonal antibodies (anti-lymphocyte)\">Monoclonal antibodies (anti-lymphocyte)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP93720\" outputclass=\"drugAction\" rev=\"1.11\" parent=\"/drugs/vedolizumab\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Vedolizumab is a monoclonal antibody that binds specifically to the &#945;<sub>4</sub>&#946;<sub>7</sub> integrin, which is preferentially expressed on gut homing T helper lymphocytes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93723\" outputclass=\"indicationsAndDose\" rev=\"1.42\" parent=\"/drugs/vedolizumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Moderate to severe active ulcerative colitis in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor (under expert supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 300&#8239;mg, then 300&#8239;mg after 2&#8239;weeks, followed by 300&#8239;mg after 4&#8239;weeks, followed by 300&#8239;mg every 8&#8239;weeks, dose to be given over 30 minutes, if treatment is interrupted or response decreases, dosing frequency may be increased&#8212;consult product literature; review treatment if no response within 10 weeks of initial dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Moderate to severe active Crohn&#8217;s disease in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor (under expert supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 300&#8239;mg, then 300&#8239;mg after 2&#8239;weeks, followed by 300&#8239;mg after 4&#8239;weeks, followed by 300&#8239;mg every 8&#8239;weeks, dose to be given over 30 minutes, if no response is observed, an additional dose of 300&#8239;mg may be given 10 weeks after initial dose; if treatment is interrupted or response decreases, dosing frequency may be increased&#8212;consult product literature; review treatment if no response within 14 weeks of initial dose.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93718\" outputclass=\"contraindications\" rev=\"1.19\" parent=\"/drugs/vedolizumab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Severe active infection</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93716\" outputclass=\"cautions\" rev=\"1.28\" parent=\"/drugs/vedolizumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Controlled chronic severe infection</ph>; <ph outputclass=\"caution\">history of recurring severe infection</ph>; <ph outputclass=\"caution\">previous treatment with natalizumab (wait at least 12 weeks between natalizumab use and initiation of vedolizumab unless potential benefit outweighs risk)</ph>; <ph outputclass=\"caution\">previous treatment with rituximab</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Risk of infection</p>\n<p>Patients must be screened for tuberculosis before starting treatment; if latent tuberculosis is diagnosed, appropriate treatment must be initiated prior to vedolizumab treatment; if tuberculosis is diagnosed during treatment, discontinue vedolizumab until infection is resolved.</p>\n<p>Patients should be brought up to date with current immunisation schedule before initiating treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93724\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/vedolizumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (vedolizumab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93729\" outputclass=\"sideEffects\" rev=\"1.21\" parent=\"/drugs/vedolizumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Acne</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">back pain</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">eczema</ph>; <ph outputclass=\"sideEffect\">erythema</ph>; <ph outputclass=\"sideEffect\">flatulence</ph>; <ph outputclass=\"sideEffect\">gastroenteritis</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">infections</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">muscle spasms</ph>; <ph outputclass=\"sideEffect\">muscular weakness</ph>; <ph outputclass=\"sideEffect\">nasal congestion</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">night sweats</ph>; <ph outputclass=\"sideEffect\">oropharyngeal pain</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">pharyngitis</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">pyrexia</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">upper respiratory tract infection</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Folliculitis</ph>; <ph outputclass=\"sideEffect\">oral candidiasis</ph>; <ph outputclass=\"sideEffect\">vulvovaginal candidiasis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dizziness</ph>; <ph outputclass=\"sideEffect\">infusion-related reactions</ph>; <ph outputclass=\"sideEffect\">listeria meningitis</ph>; <ph outputclass=\"sideEffect\">salmonella sepsis</ph>; <ph outputclass=\"sideEffect\">tuberculosis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Infusion-related reactions</p>\n<p>Infusion-related and hypersensitivity reactions have been reported. Patients should be observed continuously during each infusion for signs and symptoms of acute hypersensitivity reactions; they should also be observed for 2 hours after the initial two infusions, and for 1 hour after subsequent infusions. Discontinue treatment if a severe infusion-related or other severe reaction occurs and initiate appropriate treatment (e.g. adrenaline and antihistamines); if a mild to moderate infusion-related reaction occurs, interrupt infusion or reduce infusion rate and initiate appropriate treatment (if reaction subsides the infusion may be continued)&#8212;consider pretreatment with an antihistamine, hydrocortisone, and/or paracetamol prior to subsequent infusions in patients who experience mild to moderate infusion-related reactions.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93717\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/vedolizumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effective contraception required during and for at least 18 weeks after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93725\" outputclass=\"pregnancy\" parent=\"/drugs/vedolizumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93715\" outputclass=\"breastFeeding\" parent=\"/drugs/vedolizumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93733\" outputclass=\"monitoringRequirements\" parent=\"/drugs/vedolizumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor closely for infection before, during and after treatment&#8212;potential increased risk of opportunistic infection.</p>\n<p>Monitor for new onset or worsening neurological signs and symptoms (withhold treatment if progressive multifocal leukoencephalopathy (PML) is suspected).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93713\" outputclass=\"directionsForAdministration\" rev=\"1.24\" parent=\"/drugs/vedolizumab\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>For <i>intravenous infusion</i> (<i>Entyvio</i>\n<tm tmtype=\"reg\"/>), give intermittently <i>in</i> Sodium chloride 0.9%; allow vial to reach room temperature then reconstitute with 4.8&#8239;mL of water for injection (using a syringe with a 21&#8211;25 gauge needle); gently swirl vial for at least 15 seconds, do not shake vigorously or invert; allow to stand for up to 20 minutes (gently swirl vial if needed), leave for an additional 10 minutes if not dissolved; gently invert vial three times, withdraw 5&#8239;mL of reconstituted solution (using a syringe with a 21&#8211;25 gauge needle), and add to 250&#8239;mL of infusion fluid; gently mix and give over 30 minutes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93726\" outputclass=\"patientAndCarerAdvice\" rev=\"1.15\" parent=\"/drugs/vedolizumab\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p>Patients should be provided with a patient alert card.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93589-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/vedolizumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101368\" title=\"Powder for solution for infusion\" namespace=\"/drugs/vedolizumab/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78316\" namespace=\"/treatment-summaries/inflammatory-bowel-disease\" title=\"Inflammatory bowel disease\" count=\"1\" rel=\"backlink\">Inflammatory bowel disease</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1344\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/vedolizumab\" title=\"Vedolizumab\" count=\"1\" rel=\"link\">Vedolizumab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101368\" namespace=\"/drugs/vedolizumab/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP93589",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/vedolizumab",
    "basename": "vedolizumab",
    "title": "VEDOLIZUMAB",
    "interactants": [
        {
            "id": "bnf_int_1344",
            "label": "Vedolizumab"
        }
    ],
    "vtmid": "704257002",
    "drugClassification": [
        "Monoclonal antibodies (anti-lymphocyte)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Vedolizumab is a monoclonal antibody that binds specifically to the &#945;4&#946;7 integrin, which is preferentially expressed on gut homing T helper lymphocytes.",
                "html": "<p>Vedolizumab is a monoclonal antibody that binds specifically to the &#945;<sub>4</sub>&#946;<sub>7</sub> integrin, which is preferentially expressed on gut homing T helper lymphocytes.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Moderate to severe active ulcerative colitis in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor (under expert supervision)",
                        "html": "Moderate to severe active ulcerative colitis in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor (under expert supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 300 mg, then 300 mg after 2 weeks, followed by 300 mg after 4 weeks, followed by 300 mg every 8 weeks, dose to be given over 30 minutes, if treatment is interrupted or response decreases, dosing frequency may be increased&#8212;consult product literature; review treatment if no response within 10 weeks of initial dose.",
                        "html": "<p>Initially 300&#8239;mg, then 300&#8239;mg after 2&#8239;weeks, followed by 300&#8239;mg after 4&#8239;weeks, followed by 300&#8239;mg every 8&#8239;weeks, dose to be given over 30 minutes, if treatment is interrupted or response decreases, dosing frequency may be increased&#8212;consult product literature; review treatment if no response within 10 weeks of initial dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Moderate to severe active Crohn&#8217;s disease in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor (under expert supervision)",
                        "html": "Moderate to severe active Crohn&#8217;s disease in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor (under expert supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 300 mg, then 300 mg after 2 weeks, followed by 300 mg after 4 weeks, followed by 300 mg every 8 weeks, dose to be given over 30 minutes, if no response is observed, an additional dose of 300 mg may be given 10 weeks after initial dose; if treatment is interrupted or response decreases, dosing frequency may be increased&#8212;consult product literature; review treatment if no response within 14 weeks of initial dose.",
                        "html": "<p>Initially 300&#8239;mg, then 300&#8239;mg after 2&#8239;weeks, followed by 300&#8239;mg after 4&#8239;weeks, followed by 300&#8239;mg every 8&#8239;weeks, dose to be given over 30 minutes, if no response is observed, an additional dose of 300&#8239;mg may be given 10 weeks after initial dose; if treatment is interrupted or response decreases, dosing frequency may be increased&#8212;consult product literature; review treatment if no response within 14 weeks of initial dose.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Severe active infection",
                "html": "Severe active infection"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Controlled chronic severe infection",
                "html": "Controlled chronic severe infection"
            },
            {
                "type": "cautions",
                "textContent": "history of recurring severe infection",
                "html": "history of recurring severe infection"
            },
            {
                "type": "cautions",
                "textContent": "previous treatment with natalizumab (wait at least 12 weeks between natalizumab use and initiation of vedolizumab unless potential benefit outweighs risk)",
                "html": "previous treatment with natalizumab (wait at least 12 weeks between natalizumab use and initiation of vedolizumab unless potential benefit outweighs risk)"
            },
            {
                "type": "cautions",
                "textContent": "previous treatment with rituximab",
                "html": "previous treatment with rituximab"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Risk of infection",
                "textContent": "Patients must be screened for tuberculosis before starting treatment; if latent tuberculosis is diagnosed, appropriate treatment must be initiated prior to vedolizumab treatment; if tuberculosis is diagnosed during treatment, discontinue vedolizumab until infection is resolved.\n\nPatients should be brought up to date with current immunisation schedule before initiating treatment.",
                "html": "<p>Patients must be screened for tuberculosis before starting treatment; if latent tuberculosis is diagnosed, appropriate treatment must be initiated prior to vedolizumab treatment; if tuberculosis is diagnosed during treatment, discontinue vedolizumab until infection is resolved.</p><p>Patients should be brought up to date with current immunisation schedule before initiating treatment.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (vedolizumab).",
                "html": "<p>Appendix 1 (vedolizumab).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Acne",
                        "html": "Acne",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "back pain",
                        "html": "back pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "eczema",
                        "html": "eczema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "erythema",
                        "html": "erythema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "flatulence",
                        "html": "flatulence",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastroenteritis",
                        "html": "gastroenteritis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "infections",
                        "html": "infections",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "muscle spasms",
                        "html": "muscle spasms",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "muscular weakness",
                        "html": "muscular weakness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nasal congestion",
                        "html": "nasal congestion",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "night sweats",
                        "html": "night sweats",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "oropharyngeal pain",
                        "html": "oropharyngeal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pharyngitis",
                        "html": "pharyngitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pyrexia",
                        "html": "pyrexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "upper respiratory tract infection",
                        "html": "upper respiratory tract infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Folliculitis",
                        "html": "Folliculitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "oral candidiasis",
                        "html": "oral candidiasis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "vulvovaginal candidiasis",
                        "html": "vulvovaginal candidiasis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Dizziness",
                        "html": "Dizziness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "infusion-related reactions",
                        "html": "infusion-related reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "listeria meningitis",
                        "html": "listeria meningitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "salmonella sepsis",
                        "html": "salmonella sepsis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tuberculosis",
                        "html": "tuberculosis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Infusion-related reactions",
                "textContent": "Infusion-related and hypersensitivity reactions have been reported. Patients should be observed continuously during each infusion for signs and symptoms of acute hypersensitivity reactions; they should also be observed for 2 hours after the initial two infusions, and for 1 hour after subsequent infusions. Discontinue treatment if a severe infusion-related or other severe reaction occurs and initiate appropriate treatment (e.g. adrenaline and antihistamines); if a mild to moderate infusion-related reaction occurs, interrupt infusion or reduce infusion rate and initiate appropriate treatment (if reaction subsides the infusion may be continued)&#8212;consider pretreatment with an antihistamine, hydrocortisone, and/or paracetamol prior to subsequent infusions in patients who experience mild to moderate infusion-related reactions.",
                "html": "<p>Infusion-related and hypersensitivity reactions have been reported. Patients should be observed continuously during each infusion for signs and symptoms of acute hypersensitivity reactions; they should also be observed for 2 hours after the initial two infusions, and for 1 hour after subsequent infusions. Discontinue treatment if a severe infusion-related or other severe reaction occurs and initiate appropriate treatment (e.g. adrenaline and antihistamines); if a mild to moderate infusion-related reaction occurs, interrupt infusion or reduce infusion rate and initiate appropriate treatment (if reaction subsides the infusion may be continued)&#8212;consider pretreatment with an antihistamine, hydrocortisone, and/or paracetamol prior to subsequent infusions in patients who experience mild to moderate infusion-related reactions.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effective contraception required during and for at least 18 weeks after treatment.",
                "html": "<p>Effective contraception required during and for at least 18 weeks after treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor closely for infection before, during and after treatment&#8212;potential increased risk of opportunistic infection.\n\nMonitor for new onset or worsening neurological signs and symptoms (withhold treatment if progressive multifocal leukoencephalopathy (PML) is suspected).",
                "html": "<p>Monitor closely for infection before, during and after treatment&#8212;potential increased risk of opportunistic infection.</p><p>Monitor for new onset or worsening neurological signs and symptoms (withhold treatment if progressive multifocal leukoencephalopathy (PML) is suspected).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "For intravenous infusion (Entyvio ), give intermittently in Sodium chloride 0.9%; allow vial to reach room temperature then reconstitute with 4.8 mL of water for injection (using a syringe with a 21&#8211;25 gauge needle); gently swirl vial for at least 15 seconds, do not shake vigorously or invert; allow to stand for up to 20 minutes (gently swirl vial if needed), leave for an additional 10 minutes if not dissolved; gently invert vial three times, withdraw 5 mL of reconstituted solution (using a syringe with a 21&#8211;25 gauge needle), and add to 250 mL of infusion fluid; gently mix and give over 30 minutes.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Entyvio</i>\n<tm tmtype=\"reg\"/>), give intermittently <i>in</i> Sodium chloride 0.9%; allow vial to reach room temperature then reconstitute with 4.8&#8239;mL of water for injection (using a syringe with a 21&#8211;25 gauge needle); gently swirl vial for at least 15 seconds, do not shake vigorously or invert; allow to stand for up to 20 minutes (gently swirl vial if needed), leave for an additional 10 minutes if not dissolved; gently invert vial three times, withdraw 5&#8239;mL of reconstituted solution (using a syringe with a 21&#8211;25 gauge needle), and add to 250&#8239;mL of infusion fluid; gently mix and give over 30 minutes.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "textContent": "Patients should be provided with a patient alert card.",
                "html": "<p>Patients should be provided with a patient alert card.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP101368",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78316",
                "label": "Inflammatory bowel disease",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1344",
                "label": "Vedolizumab",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP101368",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}